NCT03214458View on ClinicalTrials.gov

Effects of Nasal High-flow Oxygen in Patients With an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

April 16, 2018

Study Completion Date

April 18, 2018

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DEVICE

Nasal high flow

The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

Temple University

OTHER

NCT03214458 - Effects of Nasal High-flow Oxygen in Patients With an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter